MEDIAN Technologies is laureate of FACCNE’s 13th Annual Business Awards
MEDIAN Technologies has received the 2014 Life Sciences Award of the French-American Chamber of Commerce of New England (FACCNE). FACCNE’s Annual Business Awards is the premier French-American business event of the year in the Boston area.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, is excited to announce that we are laureate of the 2014 Life Sciences Award of the French-American Chamber of Commerce of New England (FACCNE). The award was presented to Jerome Windsor, MEDIAN’s vice president of Business Development, Pharmaceutical Solutions, by the Consul General of France in Boston, Fabien Fieschi,during the 13th Annual Business Awards, in Boston where the company’s subsidiary, MEDIAN Technologies Inc is based.
The FACCNE Annual Business Awards celebrate the strength of French-American business relations and promote small and mid-sized companies in Greater Boston.
‘We are very proud of this award and we sincerely thank the Consul General of France in Boston, Fabien Fieschi, the FACCNE’s team and the public who has voted for MEDIAN’, said Jerome Windsor. ‘This prize creates a very nice visibility for MEDIAN, through its US subsidiary in Boston. It is a very nice signal from New England professionals actually. It is also another proof of how MEDIAN world class solutions are positively perceived. Our wish is to continue to drive growth for the company globally and contribute to help cancer patients accessing better diagnostic and care’, he added.
‘The French-American Chamber of Commerce (FACCNE) is proud to recognize Median Technologies as its 2014 Laureate in Life Sciences. The company has developed a strong expertise in medical image processing and is committed to his mission of making a dramatic impact on cancer care and research’, said Ludivine Wolczik, FACCNE Executive Director.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”